Smoldering MM trends data show increased incidence in certain patient populations
A Letter to the Editor published in the American Journal of Hematology by Rong Wang, PhD, of Yale University, and colleagues is the
Multiple Myeloma
Myeloproliferative Neoplasms
News
Lymphoma
Aggressive B-Cell Lymphomas
News
Study shows PRO data are important component of treatment efficacy, tolerability assessment
Researchers used data from the POLARIX study to compare patient-reported outcomes (PROs) against clinician-reported adverse event (AE) data and found that several AEs
Cellular Therapy
Multiple Myeloma
News
Talquetamab, teclistamab combo induces responses in patients with extramedullary myeloma
“These results show clinical benefit from this off-the-shelf, bispecific antibody combination and validate dual targeting of GPRC5D and BCMA with talquetamab plus teclistamab
Leukemia
Lymphoma
News
Pirtobrutinib significantly improves PFS in patients with treatment-naïve CLL/SLL
Data from a late-breaking abstract presented by Wojciech Jurczak, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Poland, at
Multiple Myeloma
News
‘Promising’ early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma
Preliminary phase 1 results of the inMMyCAR trial showed “promising clinical activity and manageable toxicities” associated with the investigative chimeric antigen receptor (CAR)
Multiple Myeloma
News
Teclistamab plus daratumumab improves survival compared with SOC triplet therapy in relapsed/refractory MM
A phase 3 study observed “clinically remarkable” outcomes with the combination of teclistamab and daratumumab in patients with relapsed/refractory multiple myeloma (MM). At
ASH 2025
Leukemia
Chronic Lymphocytic Leukemia
Meetings / Conferences
News
Phase 3 study finds fixed-duration treatment non-inferior to continuous treatment in CLL
A study compared the mainstay treatment approaches for chronic lymphocytic leukemia (CLL) and found that fixed-duration regimens were non-inferior to continuous treatment, offering
ASH 2025
Lymphoma
News
Extended MorningSun study results show ‘promising’ survival with subcutaneous mosunetuzumab
Additional follow-up data from the phase 2 MorningSun study showed a 91.9% overall survival rate for previously untreated patients with high-tumor burden follicular
ASH 2025
Multiple Myeloma
News
Pre-apheresis lenalidomide improves T-cell fitness in patients with myeloma undergoing transplant
Researchers found that the addition of lenalidomide before apheresis improved pharmacodynamics in patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (AHCT).
ASH 2025
Multiple Myeloma
News
Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma
A phase 1/2, first-in-human study showed that the investigational agent LBL-034 induced a response in 70.9% of patients (n=39/55) with relapsed/refractory multiple myeloma